Item 1.01. Entry into a Material Definitive Agreement.
On April 27, 2023 (the "Effective Date"), Hillstream BioPharma, Inc. (the
"Company") entered into an underwriting agreement (the "Underwriting Agreement")
with ThinkEquity LLC ("ThinkEquity"), as representative of the several
underwriters listed on Schedule 1 thereto (the "Underwriters"), relating to the
public offering (the "Offering") of 5,300,000 shares (the "Shares") of the
Company's common stock, par value $0.0001 per share (the "Common Stock"), at a
price to the public of $0.50 per Share (the "Offering Price"). Pursuant to the
terms of the Underwriting Agreement, the Company has also granted the
Underwriters a 45-day option to purchase up to an additional 795,000 shares of
Common Stock (the "Option Shares" and together with the Shares, the
"Securities") to cover over-allotments, if any, at the Offering Price less the
underwriting discounts and commissions. The net proceeds to the Company from the
sale of the Shares, after deducting the underwriting discounts and commissions
and other estimated offering expenses payable by the Company, are expected to be
approximately $2.2 million assuming no exercise by the Underwriters of their
over-allotment option for the Option Shares, or $2.6 million if the Underwriters
exercise their over-allotment option for the Option Shares in full. The Company
intends to use the net proceeds from the Offering for the advancement of
HSB-1216 and the development of other product candidates (HSB-3215 and HSB-1940)
in the Company's pipeline and general corporate purposes and working capital.
The Securities will be issued pursuant to the Company's shelf registration
statement on Form S-3 (File No. 333-270684) previously filed with the Securities
and Exchange Commission (the "Commission") on March 17, 2023 and declared
effective by the Commission on March 24, 2023 and a related prospectus
supplement dated April 27, 2023. The Offering is expected to close on or about
May 2, 2023, subject to satisfaction of customary closing conditions.
In connection with the Offering, the Company agreed to issue ThinkEquity, or its
designees, warrants (the "Representative's Warrants") to purchase such number of
shares of the Company's common stock equal to 3% of the number of Securities
sold in the Offering at an initial exercise price of $0.625 per share, subject
to adjustment. The Representative's Warrants are exercisable at any time and
from time to time, in whole or in part, during the four and one half year period
commencing 180 days from the commencement of sales of the shares of common stock
in the Offering.
Pursuant to the Underwriting Agreement, subject to certain exceptions, the
Company has agreed not to sell or otherwise dispose of any of the Company's
securities for a period ending 90 days after the Effective Date without first
obtaining the written consent of ThinkEquity. In addition, the Company's
officers and directors have agreed not to sell or otherwise dispose of any of
the Company's securities held by them for a period ending 180 days after the
Effective Date without first obtaining the written consent of ThinkEquity.
The Underwriting Agreement contains customary representations and warranties,
agreements and obligations, conditions to closing and termination provisions.
The Underwriting Agreement provides for indemnification by the Underwriters of
the Company, its directors and officers, and by the Company of the Underwriters,
for certain liabilities, including liabilities arising under the Securities Act
of 1933, as amended, and affords certain rights of contribution with respect
thereto.
The description of the terms and conditions of the Underwriting Agreement and
the Representative's Warrants set forth herein does not purport to be complete
and is qualified in its entirety by the full text of the Underwriting Agreement
(including the form of Representative's Warrant which is included as Exhibit B
thereto), a copy of which is attached hereto as Exhibit 1.1.
The legal opinion of Sheppard Mullin Richter & Hampton, LLP relating to the
legality of the issuance and sale of the Securities is attached as Exhibit 5.1
to this Current Report on Form 8-K.
This Current Report on Form 8-K does not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws of
any such state or jurisdiction.
-2-
Item 8.01 Other Events.
On April 27, 2023, the Company issued a press release announcing the Offering. A
copy of the press release is attached as Exhibit 99.1 to this Current Report on
Form 8-K and is hereby incorporated by reference herein.
On April 27, 2023, the Company issued a press release announcing the pricing of
the Offering. A copy of the press release is attached as Exhibit 99.2 to this
Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
1.1 Underwriting Agreement, dated April 27, 2023, by and between
Hillstream BioPharma, Inc. and ThinkEquity LLC
5.1 Legal Opinion of Sheppard Mullin Richter & Hampton, LLP
23.1 Consent of Sheppard Mullin Richter & Hampton, LLP (contained in
Exhibit 5.1)
99.1 Launch Press Release dated April 27, 2023
99.2 Pricing Press Release dated April 27, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
-3-
© Edgar Online, source Glimpses
THARIMMUNE, INC. 
